MP方案联合α-干扰素治疗多发性骨髓瘤临床分析  

MP Regimen Combined with Interferon-alpha in the Treatment of Multiple Myeloma

作　　者：况小红[1] 童浩 苏寒[1] 代明辉[1] 张小燕[1] 

机构地区：[1]绵阳市第三人民医院血液内科,四川绵阳621000

出　　处：《肿瘤基础与临床》2017年第4期292-294,共3页journal of basic and clinical oncology

摘　　要：目的探讨MP方案联合α-干扰素治疗多发性骨髓瘤的临床疗效和不良反应。方法 52例多发性骨髓瘤患者随机分为2组:α-干扰素组28例采用MP方案化疗联合α-干扰素治疗,对照组24例仅用MP方案化疗,每4周为1周期,连续治疗6~l2个月,比较2组患者临床疗效和不良反应。结果α-干扰素组患者总反应率为75.00%(21/28),高于对照组的58.33%(14/24)(P<0.05)。干扰素组1、3 a生存率分别为85.71%(24/28)、64.29%(18/28),对照组分别为83.33%(20/24)、54./17%(13/24)(P>0.05)。结论 MP方案联合α-干扰素治疗多发性骨髓瘤的近期疗效优于单纯MP方案化疗,且患者耐受性良好,但是并未改善患者的生存状况。Objective To investigate the clinical therapeutic efficacy and toxicities of MP regimen plus interfer- on-alpha in the treatment of patients with multiple myeloma. Methods Fifty-two patients with MM were randomized into 2 groups： 28 patients in the interferon-alpha group were treated with MP regimen plus interferon-alpha, and 24 patients in the control group were administered with MP regimen only. The clinical therapeutic efficacy and toxicities were compared in the two groups. Results The overall response rate of was 75.00% （21/28） in the interferon-al- pha group, and was 58.33 % （14/24） in the control group （ P 〈 0.05 ）. The 1 -year and 3-year survival rates were 85.71% （24/28） and 64.29% （18/28） in the interferon-alpha group, and were 83.33% （20/24） and 54.17% （13/24） in the control group （P 〉 0.05 ）. Conclusion The clinical curative efficacy on multiple myeloma of MP regimen combined with interferon-alpha is much more better than single MP chemotherapy, and it had no obvious effect on the survival of patients, the toxicities can be tolerated.

关 键 词：多发性骨髓瘤 Α-干扰素 马法兰 强的松 

分 类 号：R733.3[医药卫生—肿瘤] R730.53[医药卫生—临床医学]